July 2021 Volume 7 Issue 8

July 2021

Volume 7, Issue 8

This issue tackles racial discrimination in clinical trials, demystifies cytogenetics, and more.

Table of Contents

July 2021 Issue

Celebrating the Small Victories

Thursday, July 1st, 2021
With two months remaining in my ASH Congressional Fellowship, I recognize my time to experience working on Capitol Hill – and to get things...
You Make the Call

Reader Responses: How would you approach diathesis in a 65-year-old woman with newly diagnosed...

Thursday, July 1st, 2021
Here’s how readers responded to a You Make the Call question about a bleeding diathesis in a 65-year-old woman with newly diagnosed breast cancer. Disclaimer: ASH...

Editor’s Corner: A Shock in Paradise

Thursday, July 1st, 2021
The town of Düsseldorf is located near Germany’s western border with the Netherlands, situated on the beautiful Rhine, with its bright reflections, sailing boats,...

July 2021 Issue

Post-Transplant MRD Monitoring With Non-DTA Mutations Predicts Outcomes in AML

Thursday, July 1st, 2021
In next-generation sequencing (NGS)-based measurable residual disease (MRD) monitoring, the use of non-DNMT3A, TET2, or ASXL1 (non-DTA) mutations may predict relapse and survival following...

Older Patients With Clonal Hematopoiesis and Non-DT Mutations at Higher Risk of Mortality

Thursday, July 1st, 2021
For patients aged 80 and older, those with clonal hematopoiesis (CH) and mutational spectra other than isolated DNMT3A and TET2 (DT) variants may have...

Exploring Venetoclax Plus Azacitidine in CMML and MPNs

Thursday, July 1st, 2021
The combination of the BCL2 inhibitor venetoclax and the hypomethylating agent azacitidine has been established as a standard of care for patients with acute...

Evaluating Seroprotection for Vaccine-Preventable Infections in CAR T-Cell Recipients

Thursday, July 1st, 2021
Patients with B-cell malignancies who achieve durable remissions following treatment with chimeric antigen receptor (CAR) T-cell therapies are at risk of long-term deficiencies in...

Are Physician Perceptions of Transfusions a Barrier to Hospice Enrollment for Patients With AML?

Thursday, July 1st, 2021
Patients with acute myeloid leukemia (AML) and their caregivers generally defer end-of-life (EOL) transfusion decisions to clinicians without participating in shared decision-making. This tendency...
WIB_icon

Survival Outcomes After HLA-Haploidentical Relative Versus Matched Unrelated Donor Transplant in Acute Leukemias and...

Thursday, July 1st, 2021
In patients with acute leukemias or myelodysplastic syndromes (MDS), those who underwent haploidentical relative hematopoietic cell transplantation (haploHCT) had higher rates of grade 3-4...
WIB_icon

Less-Intensive Therapies Increase Mortality Risk, But Decrease Hospital Stay, in Older Patients With AML

Thursday, July 1st, 2021
Although the use of less-intensive therapies is associated with an increased risk of mortality in older patients with acute myeloid leukemia (AML), patients treated...
WIB_icon

Is Gene Therapy Cost-Effective for Hemophilia B?

Thursday, July 1st, 2021
A study published in Blood found the use of gene therapy for hemophilia B to be more cost-effective than prophylaxis or on-demand treatment with...
ASH Directions

ASH Responds to Investigation on SCT in Policy Custody Deaths, ASH Hematology Review Series...

Thursday, July 1st, 2021
ASH Responds to Investigation on Sickle Cell Trait Being Cited in Policy Custody Deaths The American Society of Hematology (ASH) has issued a position...
The Society Pages

SAACR Awards Indian Americans for Cancer Research Discoveries, GBT Awards $450k to SCD Care...

Thursday, July 1st, 2021
Catherine Bollard Recognized for Mentorship and Cell-Based Therapy Research Catherine Bollard, MD, MBChB, director of the Center for Cancer and Immunology Research at Children’s National...

Extended Thromboprophylaxis Does Not Reduce VTE Incidence in Hospitalized Patients With Cancer

Thursday, July 1st, 2021
The use of extended thromboprophylaxis with enoxaparin, betrixaban, or rivaroxaban does not reduce the risk of venous thromboembolic (VTE) events in hospitalized patients with...

FDA Clears IND Application for Gamma Delta T-Cell Therapy

Thursday, July 1st, 2021
The FDA has cleared an investigational new drug (IND) application for GDX012 to be examined as a therapy for patients with hematologic malignancies. GDX012...

FDA Revives Unapproved Drugs Initiative

Thursday, July 1st, 2021
The FDA is reversing the Trump administration’s decision to end the Unapproved Drugs Initiative. This program, which launched in 2006, requires pharmaceutical manufacturers to seek...

Sickle Cell Trait Cited in Police Custody Deaths

Thursday, July 1st, 2021
In a review of data on suspicious deaths from more than 30 of the largest U.S. counties, The New York Times found that sickle...

Biden Administration Requests Scientific Research Spending Hike

Thursday, July 1st, 2021
As part of the administration’s $6 trillion budget request for the 2022 fiscal year, President Joe Biden has proposed a 9% increase, or $13.5...

Congressional Bills Aim to Make Telehealth Flexibilities Permanent

Thursday, July 1st, 2021
Two Congressional bills introduced in late May are aiming to make telehealth flexibilities initiated during the COVID-19 pandemic permanent for Medicare and Medicaid recipients. The...

July 2021 Issue

Breaking Down Barriers, Building Up Trust

Thursday, July 1st, 2021
Clinical trial enrollment has lacked diversity since the start, but a global racial reckoning has brought new attention to overcoming discrimination. According to the most...

Pulling Back the Curtain: Tom DeLoughery, MD

Thursday, July 1st, 2021
In this edition, Tom DeLoughery, MD, talks about the approachability of hematologists, blending his interests in science and the outdoors through wilderness medicine, and...

What Is the Optimal Frontline Treatment for PTCL?

Thursday, July 1st, 2021
At the 2020 American Society of Hematology (ASH) Annual Meeting, researchers presented five-year results from the phase III ECHELON-2 trial, showing that patients with...

July 2021 Issue

Demystifying the Lab: Cytogenetics

Thursday, July 1st, 2021
Clinical applications abound for the study of structural abnormalties in chromosomes. The first chromosomal abnormality discovered in cancer using cytogenetics is likely still one of...
You Make the Call

You Make the Call: How would you approach diathesis in a 65-year-old woman with...

Thursday, July 1st, 2021
This month, Barbara Konkle, MD, discusses a bleeding diathesis in a 65-year-old woman with newly diagnosed breast cancer. And don't forget to check out next...